Latest & greatest articles for etanercept

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on etanercept or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on etanercept and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for etanercept

21. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404

NIHR HTA programme2016

22. Etanercept (TBC - Subsequent Entry Biologic)

Etanercept (TBC - Subsequent Entry Biologic) Etanercept | CADTH.ca Find the information you need Etanercept Etanercept Last Updated: Result type: Reports Project Number: SE0485-000 Product Line: Generic Name: Etanercept Brand Name: Brenzys Manufacturer: Merck Canada Inc. Indications: Rheumatoid arthritis, ankylosing spondylitis Submission Type: New Project Status: Active Biosimilar: Yes Date Recommendation Issued: October 25, 2016 Recommendation Type: Reimburse with clinical criteria

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2016

23. Benepali - etanercept

Benepali - etanercept 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 19 November 2015 EMA/CHMP/819219/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Benepali International non-proprietary name (...) : etanercept Procedure No. EMEA/H/C/004007/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/CHMP/819219/2015 Page 2/77 Table of contents 1. Background information on the procedure 6 1.1. Submission of the dossier 6 1.2. Steps taken for the assessment of the product 7 2. Scientific discussion 8 2.1. Introduction 8 2.2. Quality aspects 10 2.2.1. Introduction 10 2.2.2. Active Substance 10 2.2.3. Finished Medicinal

European Medicines Agency - EPARs2016

24. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis Abatacept, adalimumab, etanercept and Abatacept, adalimumab, etanercept and tocilizumab for treating juv tocilizumab for treating juvenile enile idiopathic arthritis idiopathic arthritis T echnology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta373 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y (...) to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373) © NICE 2018. All rights reserved. Subject to Notice of rights (https

National Institute for Health and Clinical Excellence - Technology Appraisals2016

25. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy 26150601 2015 11 14 2017 02 24 1468-2060 76 1 2017 Jan Annals of the rheumatic diseases Ann. Rheum. Dis. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. 51-57 10.1136/annrheumdis-2015 (...) -207588 To compare the efficacy and safety of SB4 (an etanercept biosimilar) with reference product etanercept (ETN) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) therapy. This is a phase III, randomised, double-blind, parallel-group, multicentre study with a 24-week primary endpoint. Patients with moderate to severe RA despite MTX treatment were randomised to receive weekly dose of 50 mg of subcutaneous SB4 or ETN. The primary endpoint was the American

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

26. Efficacy and Safety of Etanercept in Patients With the Enthesitis-Related Arthritis Category of Juvenile Idiopathic Arthritis: Results From a Phase III Randomized, Double-Blind Study

Efficacy and Safety of Etanercept in Patients With the Enthesitis-Related Arthritis Category of Juvenile Idiopathic Arthritis: Results From a Phase III Randomized, Double-Blind Study 25891010 2015 07 29 2015 10 13 2016 05 11 2326-5205 67 8 2015 May Arthritis & rheumatology (Hoboken, N.J.) Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study. 2240-9 10.1002/art.39145 (...) To evaluate the efficacy and safety of etanercept in patients with enthesitis-related arthritis (ERA) in juvenile idiopathic arthritis (JIA). This was a 2-phase study in JIA patients with active, refractory ERA. Phase I was an open-label, uncontrolled 24-week study period in which all patients were administered etanercept. Patients considered to be treatment responders at week 24 according to the American College of Rheumatology (ACR) Pediatric 30 (Pedi 30) criteria for improvement in juvenile

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

27. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. 26072109 2015 08 21 2015 09 03 2016 11 25 1474-547X 386 9993 2015 Aug 08 Lancet (London, England) Lancet Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. 541-51 10.1016/S0140-6736(15)60125-8 S0140-6736(15)60125-8 Ixekizumab is a humanised (...) monoclonal antibody against the proinflammatory cytokine interleukin 17A. We report two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis. In two prospective, double-blind, multicentre, phase 3 studies (UNCOVER-2 and UNCOVER-3), eligible patients were aged 18 years or older, had a confirmed diagnosis of chronic plaque psoriasis at least 6 months before baseline

Lancet2015

28. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. 26051365 2015 08 21 2015 09 03 2015 11 19 1474-547X 386 9993 2015 Aug 08 Lancet (London, England) Lancet Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. 552-61 10.1016/S0140-6736(14)62113-9 S0140-6736(14)62113-9 New therapeutic options are needed for patients with psoriasis (...) . Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis. In this study, we aimed to compare two tofacitinib doses with high-dose etanercept or placebo in this patient population. In this phase 3, randomised, multicentre, double-dummy, placebo-controlled, 12-week, non-inferiority trial, adult patients with chronic stable plaque psoriasis (for ≥12 months) who were candidates for systemic or phototherapy and had a Psoriasis Area

Lancet2015

29. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA)

Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA) 25926155 2016 04 09 2016 08 29 2016 04 09 1468-2060 75 5 2016 May Annals of the rheumatic diseases Ann. Rheum. Dis. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). 855-61 10.1136/annrheumdis-annrheumdis-2014-206747 Published evidence on the long-term safety of etanercept (ETA) and adalimumab (ADA (...) . Minden Kirsten K German Rheumatism Research Centre Berlin, a Leibniz Institute, Berlin, Germany Charité Universitätsmedizin Berlin, Children's university hospital, Berlin, Germany. eng Journal Article Observational Study Research Support, Non-U.S. Gov't 2015 04 29 England Ann Rheum Dis 0372355 0003-4967 0 Antirheumatic Agents 0 Biological Products 0 Tumor Necrosis Factor-alpha FYS6T7F842 Adalimumab OP401G7OJC Etanercept YL5FZ2Y5U1 Methotrexate IM Adalimumab adverse effects therapeutic use Adolescent

EvidenceUpdates2015

30. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis 25873634 2015 12 15 2016 04 04 2016 12 15 1468-2060 75 1 2016 Jan Annals of the rheumatic diseases Ann. Rheum. Dis. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. 52-8 10.1136/annrheumdis-2014-205726 The aim of the Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Patients Who Have Achieved a Stable Low Disease Activity-State study (...) was to investigate the effect of etanercept (ETN) dose maintenance, reduction or withdrawal on patients with rheumatoid arthritis (RA) who had already achieved stable low disease activity (LDA) on ETN 50 mg+methotrexate (MTX). Patients with RA (n=91) and stable LDA with ETN 50 mg once weekly (QW)+MTX were included. After 8 weeks with unchanged treatment, 73 patients were randomised in a double-blind design to ETN 50 mg QW+MTX (ETN50), ETN 25 mg QW+MTX (ETN25) or placebo QW+MTX (PBO) for 48 weeks. Patients who

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

31. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. 25858265 2015 04 10 2015 07 02 2016 11 25 1756-1833 350 2015 Apr 09 BMJ (Clinical research ed.) BMJ Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. h1389 10.1136 (...) /bmj.h1389 To evaluate whether a disease activity guided strategy of dose reduction of two tumour necrosis factor (TNF) inhibitors, adalimumab or etanercept, is non-inferior in maintaining disease control in patients with rheumatoid arthritis compared with usual care. Randomised controlled, open label, non-inferiority strategy trial. Two rheumatology outpatient clinics in the Netherlands, from December 2011 to May 2014. 180 patients with rheumatoid arthritis and low disease activity using adalimumab

BMJ2015 Full Text: Link to full Text with Trip Pro

32. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. OBJECTIVE: To evaluate whether a disease activity guided strategy of dose reduction of two tumour necrosis factor (TNF) inhibitors, adalimumab or etanercept, is non-inferior in maintaining disease control in patients with rheumatoid arthritis compared with usual care. DESIGN: Randomised controlled, open (...) label, non-inferiority strategy trial. SETTING: Two rheumatology outpatient clinics in the Netherlands, from December 2011 to May 2014. PARTICIPANTS: 180 patients with rheumatoid arthritis and low disease activity using adalimumab or etanercept; 121 allocated to the dose reduction strategy, 59 to usual care. INTERVENTIONS: Disease activity guided dose reduction (advice to stepwise increase the injection interval every three months, until flare of disease activity or discontinuation) or usual care

BMJ2015

33. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study

Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study 26764260 2016 01 14 2016 10 13 1468-2060 75 11 2016 Nov Annals of the rheumatic diseases Ann. Rheum. Dis. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study (...) . 1939-1944 10.1136/annrheumdis-2015-208317 A disease activity-guided dose optimisation strategy of adalimumab or etanercept (TNFi (tumour necrosis factor inhibitors)) has shown to be non-inferior in maintaining disease control in patients with rheumatoid arthritis (RA) compared with usual care. However, the cost-effectiveness of this strategy is still unknown. This is a preplanned cost-effectiveness analysis of the Dose REduction Strategy of Subcutaneous TNF inhibitors (DRESS) study, a randomised

EvidenceUpdates2015

34. Sustained remission with etanercept tapering in early rheumatoid arthritis.

Sustained remission with etanercept tapering in early rheumatoid arthritis. 25372086 2014 11 06 2014 11 14 2016 11 22 1533-4406 371 19 2014 Nov 06 The New England journal of medicine N. Engl. J. Med. Sustained remission with etanercept tapering in early rheumatoid arthritis. 1781-92 10.1056/NEJMoa1316133 We assessed the effects of reduction and withdrawal of treatment in patients with rheumatoid arthritis who had a remission while receiving etanercept-plus-methotrexate therapy. Patients (...) with early active disease who had not previously received methotrexate or biologic therapy received 50 mg of etanercept plus methotrexate weekly for 52 weeks (open-label phase). We then randomly assigned patients who had qualifying responses at weeks 39 and 52 to receive 25 mg of etanercept plus methotrexate (combination-therapy group), methotrexate alone, or placebo for 39 weeks (double-blind phase). Patients who had qualifying responses at week 39 of the double-blind phase had all treatment withdrawn

NEJM2014

35. Sustained remission with etanercept tapering in early rheumatoid arthritis.

Sustained remission with etanercept tapering in early rheumatoid arthritis. BACKGROUND: We assessed the effects of reduction and withdrawal of treatment in patients with rheumatoid arthritis who had a remission while receiving etanercept-plus-methotrexate therapy. METHODS: Patients with early active disease who had not previously received methotrexate or biologic therapy received 50 mg of etanercept plus methotrexate weekly for 52 weeks (open-label phase). We then randomly assigned patients who (...) had qualifying responses at weeks 39 and 52 to receive 25 mg of etanercept plus methotrexate (combination-therapy group), methotrexate alone, or placebo for 39 weeks (double-blind phase). Patients who had qualifying responses at week 39 of the double-blind phase had all treatment withdrawn at that time and were followed to week 65 (treatment-withdrawal phase). The primary end point was the proportion of patients with sustained remission in the double-blind phase. RESULTS: Of 306 patients enrolled

NEJM2014

36. Etanercept in the treatment of SAPHO syndrome: Which place?

Etanercept in the treatment of SAPHO syndrome: Which place? 27708894 2018 11 13 2147-9720 1 3 2014 Sep European journal of rheumatology Eur J Rheumatol Etanercept in the treatment of SAPHO syndrome: Which place? 125-128 Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome (SAPHO) is a rare disease combining skin, bone, and joint manifestations. Its treatment remains a debated issue in the absence of a valid therapeutic strategy. The experience with tumor necrosis factor alpha (TNF (...) alpha)-blocking agents is still small but encouraging. This therapy is reserved for refractory cases. The most commonly used agent is infliximab. Only few cases treated by etanercept have been reported in the literature. We report a new case treated by this biologic therapy and discuss its place in the treatment of SAPHO syndrome. A 30-year-old male, with a history of left clavicular osteitis that required surgical bone biopsy to rule out infection and malignancy, was admitted to the rheumatology

European journal of rheumatology2014 Full Text: Link to full Text with Trip Pro

37. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial

Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial 24891317 2014 07 29 2014 09 22 2016 05 11 2326-5205 66 8 2014 Aug Arthritis & rheumatology (Hoboken, N.J.) Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo (...) -controlled trial. 2091-102 10.1002/art.38721 To assess the efficacy of etanercept in the treatment of early active nonsteroidal antiinflammatory drug (NSAID)-refractory nonradiographic axial spondyloarthritis (SpA). The study population consisted of patients who met the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial SpA but not the modified New York radiographic criteria for ankylosing spondylitis (as assessed by a radiologist at the central trial site

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

38. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis

Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis 24907147 2014 10 21 2015 01 06 2015 11 19 1462-0332 53 11 2014 Nov Rheumatology (Oxford, England) Rheumatology (Oxford) Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis. 1984-93 10.1093/rheumatology/keu235 The aims (...) of this study were to investigate the short-term benefit of etanercept (ETN) + MTX vs conventional synthetic DMARDs (csDMARDs; HCQ, LEF or SSZ) + MTX in subjects with established RA. The effect of disease duration (≤2 years vs >2 years) and severity (moderate vs severe) on treatment outcomes was also assessed. Methods. Data from Asian and Latin American subjects with inadequate response to MTX were pooled from the APPEAL (ETN 25 mg biweekly + MTX or csDMARD + MTX; NCT00422227) and Latin RA (ETN 50 mg/week

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

39. Epidural injection of enbrel (etanercept Immunex Corp.) for treatment of low back pain due to lumbar disc disease

Epidural injection of enbrel (etanercept Immunex Corp.) for treatment of low back pain due to lumbar disc disease Epidural injection of enbrel (etanercept; Immunex Corp.) for treatment of low back pain due to lumbar disc disease Epidural injection of enbrel (etanercept; Immunex Corp.) for treatment of low back pain due to lumbar disc disease Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Epidural injection of enbrel (etanercept; Immunex Corp.) for treatment of low back pain due to lumbar disc disease. Lansdale: HAYES, Inc.. Health Technology Brief Publication. 2013 Authors' conclusions Low back pain (LBP) is a common ailment affecting up to 80% of all people at some point in their lifetime and approximately 28% of adults annually in the United States. The immune system protein (cytokine), tumor necrosis factor-alpha (TNF-) has been implicated in playing

Health Technology Assessment (HTA) Database.2014

40. Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis

Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis Etanercept, adalimumab, infliximab y golimumab para el tratamiento de artritis idiopática juvenil [Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis] Etanercept, adalimumab, infliximab y golimumab para el tratamiento de artritis idiopática juvenil [Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis (...) ] Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Mengarelli C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Mengarelli C. Etanercept, adalimumab, infliximab y

Health Technology Assessment (HTA) Database.2014